46-fda-to-store (FDA-to-Store: Three Disease-Mechanism Discoveries on the Real FDA Road)
Inventory item: 8496 | SKU: 2077 | Line: Blueprints
Page: https://cri-one.com/46-fda-to-store.html
Owner and author: Christopher Gabriel Brown (CRI-ONE)
Record date: 8 October 2026
Approved public wording item: medical and regulatory wording follows `D:/special/_inventory/descriptions-public/8496.md`.
1. The Record in Brief
46-fda-to-store is the "FDA-to-Store" bundle: three computational disease-mechanism discoveries (diabetes, Alzheimer's, Parkinson's) produced by Christopher Gabriel Brown's Alchemy Data V2 computational elemental analysis, each placed at Stage 0 (Discovery and Preclinical, pre-IND) of the U.S. FDA approval road, together with five Open Research companion documents and a DSHEA dietary-supplement build plan (D:/special/_inventory/descriptions-public/8496.md). It is a research and discovery IP record; it makes no treatment claim. Its earliest dated disclosures are the owner's own Depositions #201, #373 and #486, each published in the buyinvent.com catalog under a 2017 copyright mark, joined by Deposition #1399 under a 2018 mark (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). Its USPTO anchors are U.S. Application No. 19/441,975 (received 7 January 2026) and U.S. Application No. 19/445,644 (received 12 January 2026), both pending. It was first listed on the cri-one.com store on 31 August 2026 and is copyright Christopher Gabriel Brown, with a dated notice in every bundled sub-project LICENSE.
2. Proprietary - What Is Owned and How It Is Held
The source folder D:/special/46-fda-to-store holds 192 files (its own _TOC.md of 2026-10-06 lists 190 files, 20 subfolders, 12.2 MB). The delivery file of record, 46-fda-to-store__2026-09-04.zip, holds 212 entries and carries SHA-256 7677c688be82..., the same file the old store's download linked (D:/special/crione-static/delivery-v2/product_deliverables.csv). The file families are:
- Three complete sub-projects (folders 10, 11 and 12: diabetes, Alzheimer's, Parkinson's), each with a patent specification, a 20-claim summary, four patent drawings, two 11x17 charts, methodology, safety disclaimer, LICENSE, MANIFEST, CITATION.cff and CHANGELOG.
- 12 patent drawings (SVG), 6 large-format charts (SVG), 5 patent-application text files, 3 claim summaries.
- 4 Python source files (the three discovery runners and a configuration file) and 3 raw discovery data sets (JSON), with 18 findings reports including the evidence-graded V1-V3 editions.
- 5 Open Research companion texts (FDA Filing Method; Three Discoveries; one per disease), 29 HTML documents, 18 thumbnail pictures (9 SVG, 9 PNG), 6 USPTO form PDFs including the acknowledgement receipt for 19/445,644, and 4 product-download archives including the solo-chemist supplement toolkit.
- A copy of the owner's master IP register 1 light trigger.txt carrying the 2017 deposition text.
Sole ownership. Every bundled LICENSE reads: "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." and states the Work is "the exclusive property of Christopher Gabriel Brown" (Evidence 6). No assignment appears in the record; both acknowledgement receipts show the applications filed by Christopher Brown himself (Evidence 3, 4).
What a buyer receives. The bundled LICENSE states the owner's default plainly: "NO LICENSE IS GRANTED" without express written permission. The purchase grant is the checkout term at https://cri-one.com/terms: "When you buy, you buy the use of that blueprint only." The item page repeats it beside the Buy button (Evidence 10).
Secrecy measures of record (18 U.S.C. 1839(3)). The full package is delivered only to paying buyers by private download link; the mutual NDA is published at https://cri-one.com/nda/ and its full text comes with every delivery email; the purchase term is accepted at checkout (D:/special/crione-static/delivery-v2/config.json). The public item page carries only the description. The claim sets, discovery data, runner code and formulation detail never appear there.
3. First Art - The Earliest Dated Disclosure
| Date | Record | What it discloses | Source |
|---|---|---|---|
| 2017 (entry mark) | Deposition #201 | Immune-pathway insulin concept behind the diabetes discovery | entries-clean.csv; IP register line 871 |
| 2017 (entry mark) | Deposition #373 | Toxicity-and-valence screening behind the Alzheimer's discovery | entries-clean.csv; IP register line 1061 |
| 2017 (entry mark) | Deposition #486 | Computational predictive alchemy, the Alchemy Data V2 method | entries-clean.csv; IP register line 1186 |
| 2018 (entry mark) | Deposition #1399 | Deficiency-targeted vitamins, mapped to the supplement build | entries-clean.csv; IP register line 445 |
| 2025-01-07 | Diabetes discovery date of record | Diabetes mechanism analysis, Alchemy Data V2 | Evidence 9 |
| 2026-01-07 | USPTO receipt, 19/441,975 | Zinc-amino acid complexes, Alzheimer's subject | Evidence 3 |
| 2026-01-12 | USPTO receipt, 19/445,644 | Metal-amino acid complexes, Parkinson's subject | Evidence 4 |
Deposition anchors (register D:/Rebuttals/_registers/DEPOSITIONS_B.json, confirmed against D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv and D:/special/82-alchemy-calc-two/1 light trigger.txt):
- Deposition #201 (2017 catalog, IP register line 871): "immune systemic insulin. insulin medicine to magistrate through the auto immune system"
- Deposition #373 (2017 catalog, IP register line 1061): "toxic and valance testing to include but not limited to cancer and diseases like alzheimer's and substance abuse cessation aids."
- Deposition #486 (2017 catalog, IP register line 1186): "computational predictive plasma sorting lapidary alchemy studies"
- Deposition #1399 (catalog entry marked copyright 2018, IP register line 445): "g-m-vitamins are genetically modified vitamins that encourage growth to patients with severe deficiencies in a certain vitamin or cell of the body"
Each entry carries the owner's copyright mark in the catalog text. The four entries stand in the buyinvent.com catalog dump of the owner's numbered deposition series, 1,739 unique entries, each with its own copyright mark (D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md).
Defensive-publication effect. Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The owner's 2017 catalog depositions stand against every later filer claiming the immune-pathway insulin concept, toxicity-and-valence disease screening, or computational predictive alchemy as their own. A challenger must produce a dated record earlier than the 2017 entry marks disclosing the same combination, or earlier than 7 January 2026 disclosing the metal-amino acid complexes selected by an elemental-probability search. None is of record.
Prior Art Considered and Distinguished
The product folder carries no product-specific patent search file. The site provenance record for SKU 2077 (D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json) lists the portfolio-level references below; titles are as the register records them (D:/Rebuttals/_registers/PRIOR_ART_REGISTER.json).
| Reference | Title as recorded | Distinction |
|---|---|---|
| US 4,775,876 | Photon recycling light emitting diode | LED photon recycling; this package is metal-amino-acid coordination chemistry |
| US 2012/0305059 A1 | Photon recycling in an optoelectronic device | Optoelectronic device art; no amino-acid complexes |
| US 2010/0183919 A1 | Quantum dot ultracapacitor and electron battery | Energy storage art; no disease-mechanism mapping |
| US 6,175,719 B1 | Multi-Spot-Beam Satellite | Satellite payload art; different field |
| US 7,418,236 B2 | Extraterrestrial Communications Systems | Satellite-terrestrial communications; different field |
| US 11,258,379 B2 | Quantum Noise Power Devices | Energy harvesting devices; different field |
None of these references discloses metal-amino-acid coordination complexes, the Alchemy Data V2 elemental search, or the FDA-road and DSHEA packaging of this product.
4. First to File - The USPTO Record
| U.S. Application | Filed | Status of record | What it covers for this product | Source |
|---|---|---|---|---|
| 19/441,975 | 2026-01-07 | Pending (copending 2026-10-08) | Zinc-amino acid complexes, Alzheimer's sub-project (folder 11) | Evidence 3, 5 |
| 19/445,644 | 2026-01-12 | Pending (copending 2026-10-08) | Metal-amino acid complexes, Parkinson's sub-project (folder 12) | Evidence 4, 5 |
Recorded titles (D:/Rebuttals/_registers/USPTO_REGISTER.json): 19/441,975 "Zinc-Amino Acid Complexes and Methods for Treating and … Alzheimer's Disease" (confirmation [redacted], Patent Center 73872206); 19/445,644 "Novel Metal-Amino Acid Complexes and Methods for Treating Parkinson's Disease" (confirmation [redacted], Patent Center 73928275, received 01:28:59 AM ET). The USPTO Electronic Acknowledgement Receipt states that its date "will establish the filing date" of a complete new application. For both applications a further reply with fees and an extension is recorded as filed on 17 September 2026 (D:/USPTO Responses/_MERGE_NOTE_2026-09-17.md). Both stand pending as of this record. Under the AIA (16 March 2013) each application holds its own effective filing date; both predate the first store listing of this package on 31 August 2026. Marking is correct under 35 U.S.C. 292 while they are pending.
Patent pending - U.S. Application Nos. 19/441,975 and 19/445,644.
5. First to Market - The Dated Public Offering
| Date | Event | Where | Source |
|---|---|---|---|
| 2011-01-28 | First Internet Archive capture of cri-one.com | web.archive.org | D:/manager/first-to-market/wayback_evidence.json |
| 2026-08-31 | Blueprint record "46-fda-to-store" (SKU 2077) created in Enterprise blueprints | cri-one.com (old Magento store) | D:/manager/_store/export_catalog_product_20260831_201548.csv |
| 2026-09-01 | Record re-created (10:20 AM); kept in the 2026-09-07 catalog export | cri-one.com (old Magento store) | D:/manager/export_catalog_product_20260907_110415.csv |
| 2026-09-04 | Delivery file of record 46-fda-to-store__2026-09-04.zip | Delivery copies | D:/special/crione-static/delivery-v2/product_deliverables.csv |
| 2026-10-08 03:55 UTC | First new-site email campaign to US company prospects started | cri-one.com mail server | D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json |
| 2026-10-08 | Item page published on the new static site | https://cri-one.com/46-fda-to-store.html | D:/special/crione-static/site-inventory/inventory/item-8496/index.html |
| 2026-10-08 05:06 UTC | Stripe card Payment Link (created 04:56:14Z) public on the item page | https://cri-one.com/46-fda-to-store.html | D:/special/crione-static/delivery-v2/payment_links_ledger.live.json |
6. Copyright
Notice. © 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. The bundled sub-project LICENSE files carry "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." and each sub-project product card carries "© 2026 Christopher Gabriel Brown. All rights reserved." The package's copy of the IP register carries the deposition text with its 2017 marks.
Works covered. The text (specifications, claim summaries, methodology, reports, the five Open Research documents, the supplement build plan); the drawings and charts (12 patent drawings, 6 large-format charts); the source code (4 Python files); the data compilations (3 discovery data sets); and the pictures (18 thumbnails). Copyright protects this expression. The chemistry, the methods and the claimed complexes are held by the pending applications and by confidentiality (17 U.S.C. 102(b)).
Registrations anchoring the corpus (verified in D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json): 20 registrations of record, TX 7-491-093 (invent cloud, effective 2010-10-01) through TX 9-504-677 (estimated, effective 2025-05-06). Registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)); a certificate made before or within five years after first publication is prima facie evidence of validity (17 U.S.C. 410(c)).
Human authorship. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the text of the numbered depositions written by Christopher Gabriel Brown, and his selection, coordination and arrangement of each package.
Notice practice. Copyright arose on fixation (17 U.S.C. 102(a)). The written notice in the owner's own name on every LICENSE and product card defeats an innocent-infringer defense (17 U.S.C. 401(d)).
7. Firm Rebuttals
Challenge 1 - "Metal-amino acid complexes are old chemistry. Nothing here is original."
Rebuttal. The owner's own reports cite the published zinc and magnesium literature by PMID and grade it (Evidence 9); the package claims what that literature does not: specific coordination complexes selected by the Alchemy Data V2 elemental search, organised into 20-claim sets (the Alzheimer's set: 4 independent and 16 dependent claims; Evidence 7). The computational predictive alchemy behind the selection is dated by the owner's 2017 catalog Deposition #486, and the toxicity-and-valence screening approach by Deposition #373 (Evidence 1, 2). The six references of record are photonics, energy-storage and satellite art (Section 3). A challenger must produce a dated record disclosing the same complexes, the same selection method and the same claim structure before 7 January 2026. None is of record.
Challenge 2 - "Someone else filed on zinc complexes first."
Rebuttal. The USPTO acknowledgement receipts fix 7 January 2026 for 19/441,975 and 12 January 2026 for 19/445,644 (Evidence 3, 4). Under the AIA each application holds its own effective filing date. The underlying concepts stand in the owner's catalog depositions under 2017 copyright marks (Evidence 1, 2) and act as prior art under 35 U.S.C. 102(a)(1) against any later filer. A challenger must name an earlier application and show it claims the same combination.
Challenge 3 - "The applications are only pending, so there is nothing to respect."
Rebuttal. The owner holds two pending applications, correctly marked "patent pending" under 35 U.S.C. 292, and further replies with fees are recorded as filed on 17 September 2026 (Evidence 5). Pending status is a USPTO-dated record of the disclosure. The package expression is copyrighted and the full package is held confidential under purchase terms and an NDA.
Challenge 4 - "The research was published, so anyone may use it."
Rebuttal. Publication fixes the owner's priority; it grants no license. The public page carries only the description; the claim sets, data and code go only to paying buyers, whose grant is the use of the blueprint only, and the bundled LICENSE states "NO LICENSE IS GRANTED" (Evidence 6). The dated disclosures act defensively against later filers.
Challenge 5 - "This is a medical claim. It promises a treatment."
Rebuttal. The product is a research and discovery IP record. Its approved public wording places all three discoveries at Stage 0 (Discovery and Preclinical, pre-IND), states they are not FDA-approved drugs, states patent-pending is not FDA-approved, and directs readers to a licensed physician (Evidence 9). The METHODOLOGY states that discovery scores reflect database coverage and mechanism overlap and that probability values are mathematical calculations from the Alchemy system (Evidence 8). The supplement build plan limits itself to structure/function statements with the mandatory FDA disclaimer. The application titles are recorded as filed with the USPTO; the product itself makes no treatment claim.
Challenge 6 - "The figures are impossible: 24.4 million combinations against 257,500 methods."
Rebuttal. The figures are defined and sourced in the owner's own files: the Alchemy Data V2 system "scanned 24.4 million+ element combinations against 257,500 synthesis methods" and cross-referenced findings against PubMed-indexed literature (Evidence 9). The raw output stands in the three discovery data sets in the package, with per-compound probability values computed by the Alchemy system; the diabetes top finding C-H-O-N-Zn is recorded at Alchemy Score 50.0/100, 23 synthesis methods, probability 0.002757. The METHODOLOGY defines each score (Evidence 8). A challenger must rerun the shipped runner code against the shipped data and show a different result.
Challenge 7 - "AI wrote this, so there is no copyright."
Rebuttal. The depositions are the owner's: Depositions #201, #373, #486 and #1399 were written by Christopher Gabriel Brown and carry his 2017 and 2018 copyright marks (Evidence 1, 2). The selection of the three diseases, the arrangement into sub-projects and the FDA-road and DSHEA framing are his. Protection covers that human-authored expression and his selection, coordination and arrangement (U.S. Copyright Office guidance, March 2023).
Challenge 8 - "The dates can be faked."
Rebuttal. The dates rest on fixed records and third parties. The deposition text carries its 2017 and 2018 copyright marks in the buyinvent.com catalog dump, fingerprinted below (Evidence 2). The Internet Archive independently captured cri-one.com on 28 January 2011 and buyinvent.com on 5 March 2014 (Evidence 14). The USPTO time-stamped both receipts (Evidence 3, 4). Stripe time-stamped the Payment Link at 04:56:14Z on 8 October 2026 (Evidence 11). Every file in the Evidence Index is fingerprinted with SHA-256 in D:/Rebuttals/_evidence/8496.sha256; the delivery file's hash matches the file the old store linked (D:/special/crione-static/delivery-v2/product_deliverables.csv).
Challenge 9 - "It is just an idea in a description."
Rebuttal. The package is concrete work: three patent specifications, 20 claims per sub-project, 12 patent drawings, 6 large-format charts, 4 Python source files, 3 discovery data sets, 18 findings reports, 5 Open Research documents, USPTO form PDFs and a supplement toolkit, delivered as a 212-entry file with a fixed SHA-256 (Evidence 15).
Challenge 10 - "The diabetes discovery has no application, so it is open."
Rebuttal. The diabetes sub-project is held in the package as a complete 20-claim specification under the owner's copyright and confidentiality. Its concept is published in the owner's catalog Deposition #201 under a 2017 copyright mark (Evidence 1, 2), and the discovery carries a recorded discovery date of 7 January 2025 (Evidence 9). That catalog deposition stands as prior art against any later filer on that concept.
8. Evidence Index
| # | File | SHA-256 (first 16 hex) | What it proves |
|---|---|---|---|
| 1 | D:/special/82-alchemy-calc-two/1 light trigger.txt | 2dcb359de3f1b56d | Master IP register: Depositions 201, 373, 486, 1399 |
| 2 | D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv | ad3b87e885814dbb | 2017 catalog text with copyright marks |
| 3 | D:/USPTO Responses/Receipts/N417diabetes.pdf | a2aa6ac673f1873f | USPTO receipt 19/441,975, 2026-01-07 |
| 4 | D:/USPTO Responses/Receipts/N417parkinsons.pdf | bb5b87bad4927f62 | USPTO receipt 19/445,644, 2026-01-12 |
| 5 | D:/USPTO Responses/_MERGE_NOTE_2026-09-17.md | 7795fddecd6ca972 | Replies with fees recorded 2026-09-17 |
| 6 | D:/special/46-fda-to-store/11-alzheimers-cure-discovery/LICENSE | c5b73bacf23e9427 | Dated notice, exclusive ownership, no license granted |
| 7 | D:/special/46-fda-to-store/11-alzheimers-cure-discovery/CLAIMS_SUMMARY.md | dc248a0df1cfa8c6 | 20-claim structure, 4 independent claims |
| 8 | D:/special/46-fda-to-store/11-alzheimers-cure-discovery/METHODOLOGY.md | 03b609570a54bf98 | How scores and probabilities are defined |
| 9 | D:/special/_inventory/descriptions-public/8496.md | 0ade1528ed89b4d7 | Approved public wording, package contents, figures |
| 10 | D:/special/crione-static/site-inventory/inventory/item-8496/index.html | b21d3ee5544614fc | Public item page and purchase term |
| 11 | D:/special/crione-static/delivery-v2/payment_links_ledger.live.json | 96abb64653254b86 | Payment Link created 2026-10-08T04:56:14Z |
| 12 | D:/manager/export_catalog_product_20260907_110415.csv | 12be9abf793c5f86 | Old store record, SKU 2077 |
| 13 | D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json | 4245280e5b3aea54 | Prior-art references considered for SKU 2077 |
| 14 | D:/manager/first-to-market/wayback_evidence.json | a0dde412013594b5 | Internet Archive first captures |
| 15 | D:/special-disc/46-fda-to-store__2026-09-04.zip | 7677c688be82e06a | Delivery file of record |
9. Notice Line
© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/441,975 and 19/445,644.
cri-one.com/46-fda-to-store.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.Go to cart